Therapeutic Potential of Oral Tofacitinib in Alopecia Areata: A Retrospective Study

    B. S. Chandrashekar, Varsha R. Koti, Madura Chandu, Chaithra Shenoy, Abhijna Chandar, M. S. Roopa, Nagamani Narayana
    Image of study
    TLDR Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
    This retrospective study evaluated the long-term efficacy and safety of oral tofacitinib in 69 patients with various forms of alopecia areata (AA) from January 2017 to October 2022. The results showed that 46.5% of patients had a very good response, and 4.3% had an excellent response, with 44.9% experiencing no recurrence. Minimal adverse effects were reported, such as acneiform eruptions and upper respiratory tract infections. The study concluded that tofacitinib is a promising treatment for moderate to severe AA, with no serious side effects observed, making it a potential primary treatment option.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 6 results

    Related Research

    2 / 2 results